Clostridium Infections - Pipeline Review, H1 2012
Global Markets Direct
January 23, 2012 162 Pages - SKU: GMD6775937
|
|
Clostridium Infections - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Clostridium Infections - Pipeline Review, H1 2012', provides an overview of the Clostridium Infections therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Infections. 'Clostridium Infections - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Clostridium Infections.
- A review of the Clostridium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Clostridium Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Clostridium Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Clostridium Infections pipeline depth and focus of Clostridium Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Clostridium Infections Overview
- Therapeutics Development
- An Overview of Pipeline Products for Clostridium Infections
- Clostridium Infections Therapeutics under Development by Companies
- Clostridium Infections Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Clostridium Infections Therapeutics - Products under Development by Companies
- Clostridium Infections Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Clostridium Infections Therapeutics Development
- Sanofi-Aventis
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Cangene Corporation
- Takeda Pharmaceutical Company Limited
- Nanotherapeutics, Inc.
- Actelion Ltd
- Cubist Pharmaceuticals, Inc.
- Mitsubishi Tanabe Pharma Corporation
- ViroPharma Incorporated
- Progenics Pharmaceuticals, Inc.
- Avexa Limited
- Optimer Pharmaceuticals, Inc.
- Paratek Pharmaceuticals, Inc.
- Intercell AG
- AVANIR Pharmaceuticals
- Oragenics, Inc.
- XOMA Ltd.
- Immuron Limited
- Lipoxen PLC
- Green Cross Corporation
- LG Life Sciences, Ltd
- Panacea Biotec Limited
- Summit Corporation plc
- PolyMedix, Inc.
- e-Therapeutics plc
- ActogeniX NV
- Novacta Biosystems Limited
- Osel Inc.
- iBio, Inc.
- DynPort Vaccine Company LLC
- Molecular Targeting Technologies, Inc.
- Clostridium Infections - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- CB-183,315 - Drug Profile
- Xenerex - Drug Profile
- Dificid - Drug Profile
- ACAM-CDIFF - Drug Profile
- MU1140 - Drug Profile
- AVX13616 - Drug Profile
- Rifalazil - Drug Profile
- Oritavancin - Drug Profile
- LipoTet - Drug Profile
- ETX1153c - Drug Profile
- NVB302 - Drug Profile
- MK-3415A - Drug Profile
- XOMA 3AB - Drug Profile
- SMT 19969 - Drug Profile
- PMX-30016 - Drug Profile
- Ramoplanin - Drug Profile
- GSK 792014 + Infanrix + Pediarix - Drug Profile
- V501 + Menactra + Adacel - Drug Profile
- TdaP Vaccine - Drug Profile
- GSK2202083A + Prevenar 13 + Rotarix - Drug Profile
- Actacel - Drug Profile
- DTaP-IPV-HB-PRP~T + Prevnar - Drug Profile
- Heptavalent Combination Vaccine - Drug Profile
- Tdap - Drug Profile
- VP 20621 - Drug Profile
- MIYA-BM - Drug Profile
- Botulism Antitoxin Heptavalent - Drug Profile
- GSK217744 Formulation B - Drug Profile
- GSK217744 Formulation A - Drug Profile
- Tetracyclins For Clostridium - Drug Profile
- Hexaxim - Drug Profile
- Quadracel - Drug Profile
- Clostridium Difficile Antibodies - Drug Profile
- Cadazolid - Drug Profile
- IC84 - Drug Profile
- DtwP-HB-Hib (Recon) Vaccine - Drug Profile
- Tetanus Toxin Monoclonal Antibody - Drug Profile
- rBV A/B - Drug Profile
- BK-4SP - Drug Profile
- V419 + Pentacel + Prevnar 13 + RotaTeq - Drug Profile
- C.Difficile Holotoxins + Alum Adjuvant - Drug Profile
- Chimera Toxins + Alum Adjuvant - Drug Profile
- V419 + Daptacel + PedvaxHIB + Prevnar 13 + RotaTeq - Drug Profile
- GC1107 - Drug Profile
- My Five - Drug Profile
- IMM 308 - Drug Profile
- KD-332 - Drug Profile
- Easysix - Drug Profile
- MGB-BP-3 - Drug Profile
- TAK-361S - Drug Profile
- SMT21829 - Drug Profile
- Botulinum Toxin Vaccine - Drug Profile
- ActoBiotic For Clostridium Difficile Enteropathy - Drug Profile
- Clostridium Infections Therapeutics - Drug Profile Updates
- Clostridium Infections Therapeutics - Discontinued Products
- Clostridium Infections Therapeutics - Dormant Products
- Clostridium Infections - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Clostridium Infections, H1 2012
- Products under Development for Clostridium Infections - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Development by Companies, H1 2012 (Contd..1)
- Number of Products under Development by Companies, H1 2012 (Contd..2)
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Development by Companies, H1 2012 (Contd..1)
- Products under Development by Companies, H1 2012 (Contd..2)
- Products under Investigation by Universities/Institutes, H1 2012
- Sanofi-Aventis, H1 2012
- GlaxoSmithKline plc, H1 2012
- Merck & Co., Inc., H1 2012
- Cangene Corporation, H1 2012
- Takeda Pharmaceutical Company Limited, H1 2012
- Nanotherapeutics, Inc., H1 2012
- Actelion Ltd, H1 2012
- Cubist Pharmaceuticals, Inc., H1 2012
- Mitsubishi Tanabe Pharma Corporation, H1 2012
- ViroPharma Incorporated, H1 2012
- Progenics Pharmaceuticals, Inc., H1 2012
- Avexa Limited, H1 2012
- Optimer Pharmaceuticals, Inc., H1 2012
- Paratek Pharmaceuticals, Inc., H1 2012
- Intercell AG, H1 2012
- AVANIR Pharmaceuticals, H1 2012
- Oragenics, Inc., H1 2012
- XOMA Ltd., H1 2012
- Immuron Limited, H1 2012
- Lipoxen PLC, H1 2012
- Green Cross Corporation, H1 2012
- LG Life Sciences, Ltd, H1 2012
- Panacea Biotec Limited, H1 2012
- Summit Corporation plc, H1 2012
- PolyMedix, Inc., H1 2012
- e-Therapeutics plc, H1 2012
- ActogeniX NV, H1 2012
- Novacta Biosystems Limited, H1 2012
- Osel Inc., H1 2012
- iBio, Inc., H1 2012
- DynPort Vaccine Company LLC, H1 2012
- Molecular Targeting Technologies, Inc., H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Clostridium Infections Therapeutics - Drug Profile Updates
- Clostridium Infections Therapeutics - Discontinued Products
- Clostridium Infections Therapeutics - Dormant Products
- Clostridium Infections Therapeutics - Dormant Products (Contd..1)
- List of Figures
- Number of Products under Development for Clostridium Infections, H1 2012
- Products under Development for Clostridium Infections - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Discovery and Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Drug Discovery Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
